SCHEMBL4597265

SCHEMBL4597265

CCOC(=O)c1cc2cc(Nc3c(NCc4cccc(O)c4)c(=O)c3=O)ccc2[nH]1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 7/20 0.53
MMP2 P08253 5/20 0.52
ROCK2 O75116 2/20 0.49
GSK3B P49841 2/20 0.49
ROCK1 Q13464 2/20 0.49
PRKG1 Q13976 2/20 0.49
CLK4 Q9HAZ1 2/20 0.49
PLK4 O00444 1/20 0.49
CHEK1 O14757 1/20 0.49
DAPK3 O43293 1/20 0.49
DYRK3 O43781 1/20 0.49
JAK2 O60674 1/20 0.49
PRKD3 O94806 1/20 0.49
MAP4K4 O95819 1/20 0.49
CHEK2 O96017 1/20 0.49
PRKCG P05129 1/20 0.49
CDK1 P06493 1/20 0.49
ROS1 P08922 1/20 0.49
PIM1 P11309 1/20 0.49
PRKACA P17612 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4907935 0.84 ROCK2 (0.53) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL4908137 0.77 ROCK1 (0.52) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL4898803 0.77 ROCK2 (0.50) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL4908829 0.76 ROCK2 (0.52) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL28230399 0.75 MMP13 (0.70) MMP13MMP2MAPK1KDM4EALDH1A1
SCHEMBL1229167 0.74 ROCK2 (0.75) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL829213 0.73 KDM4E (0.76) MMP13MMP2KDM4EALDH1A1HPGD
SCHEMBL4917069 0.73 EGFR (0.50) ROCK2GSK3BROCK1PRKG1CLK4
SCHEMBL4900190 0.73 ROCK1 (0.49) MMP13ROCK2GSK3BROCK1PRKG1
SCHEMBL6001724 0.73 MMP13 (0.76) MMP13MMP2KDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US claimed
EP-1910312-A1 QUADRATIC ACID II DERIVATIVES Merck Patent GmbH (DE) 2008-04-16 EP claimed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO claimed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
US-20080234266-A1 Squaric Acid Derivatives II MERCK PATENT GESELLSCHAFT (DE) 2008-09-25 US disclosed
WO-2007014608-A1 QUADRATIC ACID II DERIVATIVES MERCK PATENT GMBH (DE) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080234266-A1 Squaric Acid Derivatives II CHEK2, CHEK1, SGK3 MMP13 4829/4885MMP2 4688/4885ROCK2 662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.